Convergence of regenerative medicine and synthetic biology to develop standardized and validated models of human diseases with clinical relevance

Current Opinion in Biotechnology

Volumn 35, Issue , 2015, Pages 127-132

  Hutmacher, Dietmar Werner ^a,b,c   Holzapfel, Boris Michael ^a,d   De Juan Pardo, Elena Maria ^a,e   Pereira, Brooke Anne ^e   Ellem, Stuart John ^e   Loessner, Daniela ^a   Risbridger, Gail Petuna ^e  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL EQUIPMENT; IMPLANTS (SURGICAL); TISSUE ENGINEERING;

BIOMEDICAL RESEARCH; HEALTHY TISSUES; MEDICAL DEVICES; PERSONALIZED MEDICINES; REGENERATIVE MEDICINE; SYNTHETIC BIOLOGY; TISSUE ENGINEERED CONSTRUCTS; TISSUE-ENGINEERING TECHNIQUES;

TISSUE;

BIOLOGICAL MODEL; BIOREACTOR; CELL SELECTION; DISEASE MODEL; EXPLANT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDICAL RESEARCH; NONHUMAN; PERSONALIZED MEDICINE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS MODEL; REGENERATIVE MEDICINE; REVIEW; STANDARDIZATION; SYNTHETIC BIOLOGY; TISSUE ENGINEERING; TISSUE IMPLANT; TISSUE INJURY; VALIDATION PROCESS; VALIDATION STUDY; XENOGRAFT; ANIMAL; PROCEDURES; PROSTHESES AND ORTHOSES;

ANIMALS; BIOMEDICAL RESEARCH; HUMANS; PRECISION MEDICINE; PROSTHESES AND IMPLANTS; REGENERATIVE MEDICINE; SYNTHETIC BIOLOGY; TISSUE ENGINEERING;

EID: 84934997307     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2015.06.001     Document Type: Review

References (49)

1. Pavelić K., Martinović T., Pavelić S.K. Do we understand the personalized medicine paradigm?. EMBO reports 2014, e201439609.
2. McArthur G.A., Chapman P.B., Robert C., Larkin J., Haanen J.B., Dummer R., Ribas A., Hogg D., Hamid O., Ascierto P.A. Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014, 15:323-332.
3. Holzapfel B.M., Reichert J.C., Schantz J.-T., Gbureck U., Rackwitz L., Noeth U., Jakob F., Rudert M., Groll J., Hutmacher D.W. How smart do biomaterials need to be? A translational science and clinical point of view. Adv Drug Deliv Rev 2013, 65:581-603.
4. Hutmacher D.W., Schantz J.T., Lam C.X.F., Tan K.C., Lim T.C. State of the art and future directions of scaffold-based bone engineering from a biomaterials perspective. J Tissue Eng Regenerative Med 2007, 1:245-260.
5. Atala A. Engineering organs. Curr Opin Biotechnol 2009, 20:575-592.
6. Cheng A.Y., García A.J. Engineering the matrix microenvironment for cell delivery and engraftment for tissue repair. Curr Opin Biotechnol 2013, 24:864-871.
7. Hutmacher D.W. Biomaterials offer cancer research the third dimension. Nat Mater 2010, 9:90-93.
8. Infanger D.W., Lynch M.E., Fischbach C. Engineered culture models for studies of tumor-microenvironment interactions. Annual Rev Biomed Eng 2013, 15:29-53.
9. Perrin S. Preclinical research: make mouse studies work. Nature 2014, 507:423-425.
10. Paul S.M., Mytelka D.S., Dunwiddie C.T., Persinger C.C., Munos B.H., Lindborg S.R., Schacht A.L. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010, 9:203-214.
11. Blum H.E. Advances in individualized and regenerative medicine. Adv Med Sci 2014, 59:7-12.
12. Purnick P.E., Weiss R. The second wave of synthetic biology: from modules to systems. Nat Rev Mol Cell Biol 2009, 10:410-422.
13. Gardner T.S., Hawkins K. Synthetic biology: evolution or revolution? A co-founder's perspective. Curr Opin Chem Biol 2013, 17:871-877.
14. Hutmacher D.W., Loessner D., Rizzi S., Kaplan D.L., Mooney D.J., Clements J.A. Can tissue engineering concepts advance tumor biology research?. Trends Biotechnol 2010, 28:125-133.
15. Torisawa Y.-s., Spina C.S., Mammoto T., Mammoto A., Weaver J.C., Tat T., Collins J.J., Ingber D.E. Bone marrow-on-a-chip replicates hematopoietic niche physiology in vitro. Nat Methods 2014, 11:663-669.
16. Loessner D., Holzapfel B.M., Clements J.A. Engineered microenvironments provide new insights into ovarian and prostate cancer progression and drug responses. Adv Drug Deliv Rev 2014, 79:193-213.
17. Holzapfel B.M., Thibaudeau L., Hesami P., Taubenberger A., Holzapfel N.P., Mayer-Wagner S., Power C., Clements J., Russell P., Hutmacher D.W. Humanised xenograft models of bone metastasis revisited: novel insights into species-specific mechanisms of cancer cell osteotropism. Cancer Metastasis Rev 2013, 32:129-145.
18. Holzapfel B.M., Wagner F., Loessner D., Holzapfel N.P., Thibaudeau L., Crawford R., Ling M.-T., Clements J.A., Russell P.J., Hutmacher D.W. Species-specific homing mechanisms of human prostate cancer metastasis in tissue engineered bone. Biomaterials 2014, 35:4108-4115.
19. Thibaudeau L., Taubenberger A.V., Holzapfel B.M., Quent V.M., Fuehrmann T., Hesami P., Brown T.D., Dalton P.D., Power C.A., Hollier B.G. A tissue-engineered humanized xenograft model of human breast cancer metastasis to bone. Disease Models Mech 2014, 7:299-309.
20. Werner H.M., Mills G.B., Ram P.T. Cancer Systems Biology: a peek into the future of patient care?. Nat Rev Clin Oncol 2014, 11:167-176.
21. Feigl B., Hutmacher D. Eyes on 3D-current 3D biomimetic disease concept models and potential applications in age-related macular degeneration. Adv Healthcare Mater 2013, 2:1056-1062.
22. Feder-Mengus C., Ghosh S., Reschner A., Martin I., Spagnoli G.C. New dimensions in tumor immunology: what does 3D culture reveal?. Trends Mol Med 2008, 14:333-340.
23. Ellem S.J., De-Juan-Pardo E.M., Risbridger G.P. In vitro modeling of the prostate cancer microenvironment. Adv Drug Deliv Rev 2014, 79:214-221.
24. Loessner D., Stok K.S., Lutolf M.P., Hutmacher D.W., Clements J.A., Rizzi S.C. Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials 2010, 31:8494-8506.
25. Khetani S.R., Bhatia S.N. Engineering tissues for in vitro applications. Curr Opin Biotechnol 2006, 17:524-531.
26. Bhatia S.N., Ingber D.E. Microfluidic organs-on-chips. Nat Biotechnol 2014.
27. Guvendiren M., Burdick J.A. Engineering synthetic hydrogel microenvironments to instruct stem cells. Curr Opin Biotechnol 2013, 24:841-846.
28. Schenke-Layland K., Nerem R.M. In vitro human tissue models-moving towards personalized regenerative medicine. Adv Drug Deliv Rev 2011, 63:195-196.
29. Griffith L.G., Swartz M.A. Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol 2006, 7:211-224.
30. Guillotin B., Guillemot F. Cell patterning technologies for organotypic tissue fabrication. Trends Biotechnol 2011, 29:183-190.
31. Place E.S., Evans N.D., Stevens M.M. Complexity in biomaterials for tissue engineering. Nat Mater 2009, 8:457-470.
32. Baldwin J., Antille M., Bonda U., De-Juan-Pardo E.M., Khosrotehrani K., Ivanovski S., Petcu E.B., Hutmacher D.W. In vitro pre-vascularisation of tissue-engineered constructs A co-culture perspective. Vascular Cell 2014, 6:13.
33. Ferreira L.M., Mostajo-Radji M.A. How induced pluripotent stem cells are redefining personalized medicine. Gene 2013, 520:1-6.
34. Yum K., Hong S.G., Healy K.E., Lee L.P. Physiologically relevant organs on chips. Biotechnol J 2014, 9:16-27.
35. Ma L., Barker J., Zhou C., Li W., Zhang J., Lin B., Foltz G., Küblbeck J., Honkakoski P. Towards personalized medicine with a three-dimensional micro-scale perfusion-based two-chamber tissue model system. Biomaterials 2012, 33:4353-4361.
36. Sato T., Stange D.E., Ferrante M., Vries R.G., Van Es J.H., Van den Brink S., Van Houdt W.J., Pronk A., Van Gorp J., Siersema P.D. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 2011, 141:1762-1772.
37. Cheung K.J., Gabrielson E., Werb Z., Ewald A.J. Collective invasion in breast cancer requires a conserved basal epithelial program. Cell 2013, 155:1639-1651.
38. Alépée N., Bahinski T., Daneshian M., De Wever B., Fritsche E., Goldberg A., Hansmann J., Hartung T., Haycock J., Hogberg H., et al. State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology. ALTEX 2014, 31:441-477.
39. Gjorevski N., Ranga A., Lutolf M.P. Bioengineering approaches to guide stem cell-based organogenesis. Development 2014, 141:1794-1804.
40. Holzapfel B.M., Wagner F., Thibaudeau L., Levesque J.-P., Hutmacher D.W. Concise review: humanized models of tumor immunology in the 21st century: convergence of cancer research and tissue engineering. Stem Cells 2015, 33:1696-1704.
41. Shamir E.R., Ewald A.J. Three-dimensional organotypic culture: experimental models of mammalian biology and disease. Nat Rev Mol Cell Biol 2014, 15:647-664.
42. Williamson A., Singh S., Fernekorn U., Schober A. The future of the patient-specific body-on-a-chip. Lab on a Chip 2013, 13:3471-3480.
43. Xu X., Farach-Carson M.C., Jia X. Three-dimensional in vitro tumor models for cancer research and drug evaluation. Biotechnol Adv 2014, 32:1256-1268.
44. Couzin-Frankel J. The littlest patient. Science 2014, 346:24-27.
45. Brehm M.A., Shultz L.D., Greiner D.L. Humanized mouse models to study human diseases. Curr Opin Endocrinol Diabetes Obesity 2010, 17:120.
46. Shultz L.D., Brehm M.A., Garcia-Martinez J.V., Greiner D.L. Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol 2012, 12:786-798.
47. Shultz L.D., Ishikawa F., Greiner D.L. Humanized mice in translational biomedical research. Nat Rev Immunol 2007, 7:118-130.
48. Cosgun K.N., Rahmig S., Mende N., Reinke S., Hauber I., Schäfer C., Petzold A., Weisbach H., Heidkamp G., Purbojo A. Kit regulates HSC engraftment across the human-mouse species barrier. Cell Stem Cell 2014, 15:227-238.
49. Rongvaux A., Takizawa H., Strowig T., Willinger T., Eynon E.E., Flavell R.A., Manz M.G. Human hemato-lymphoid system mice: current use and future potential for medicine. Annual Rev Immunol 2013, 31:635.